OASA PHARADR | Sales 2021 | 28.87M 2.64M | Sales 2022 | 3.04M 278K | Capitalization | 234M 21.38M |
|---|---|---|---|---|---|
| Net income 2021 | -133M -12.18M | Net income 2022 | -357M -32.69M | EV / Sales 2021 | 37.7 x |
| Net cash position 2021 | 86.84M 7.95M | Net cash position 2022 | 134M 12.3M | EV / Sales 2022 | 32.6 x |
| P/E ratio 2021 |
-8.86
x | P/E ratio 2022 |
-0.6
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 61.42% |
More Fundamentals
* Assessed data
More news
Latest transcript on OASA PHARADR
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Erik Kinnman
CEO | Chief Executive Officer | 66 | 23-01-22 |
Robert Maiorana
DFI | Director of Finance/CFO | 64 | 20-11-30 |
Heidi Ramstad
CTO | Chief Tech/Sci/R&D Officer | 55 | 21-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 44 | 19-03-18 | |
Hege Hellstrom
BRD | Director/Board Member | 59 | 19-09-25 |
Pål Ryfors
BRD | Director/Board Member | 41 | 22-05-24 |
Vivesto AB, formerly Oasmia Pharmaceutical AB is a Swecen-based pharma company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in advanced ovarian cancer, and docetaxel micellar, which is being developed for widespread prostate cancer. Vivesto's patented technology platform is developed to improve the water solubility, efficacy and safety of drugs.
Sector
Pharmaceuticals
Calendar
2024-05-22
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| +25.74% | 661B | |
| +26.74% | 566B | |
| -6.75% | 352B | |
| +19.47% | 332B | |
| +3.28% | 283B | |
| +13.43% | 231B | |
| +4.71% | 200B | |
| -9.53% | 195B | |
| -4.23% | 145B |
